Chondrosarcoma Overview

Save information for later
Sign Up

Learn About Chondrosarcoma

View Main Condition: Brain Tumor

What is the definition of Chondrosarcoma?
Chondrosarcoma is a rare, slow-growing form of bone cancer that develops in the bones or the cartilage. The cartilage is the connective tissue from which most bones develop. Chondrosarcomas appear in bones or cartilage at the base of the skull, arms, scapula, ribs, pelvis, knee, femur (thighbone), or tibia.
What are the symptoms of Chondrosarcoma?
Symptoms of chondrosarcoma depend on the cartilage or bone that is involved and include the appearance of a large mass on the affected bone, swelling and pressure surrounding the mass, muscle wasting, gradually increasing pain not relieved with rest, constant pain that worsens at night, and fracture of the affected bone. A chondrosarcoma that appears on the spine may cause weakness, numbness, and an inability to control the release of urine (incontinence) or bowels.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Chondrosarcoma?
Treatment for chondrosarcoma depends on a patient’s age, overall health, medical history, the stage and location of the cancer, and may include surgery to remove the tumor, bone reconstructive surgery, amputation, radiation therapy, chemotherapy, and physical therapy.
Who are the top Chondrosarcoma Local Doctors?
Melissa Burgess
Elite in Chondrosarcoma
Dr. Melissa Burgess
Hematology Oncology
Elite in Chondrosarcoma
Dr. Melissa Burgess
Hematology Oncology

UPMC Hillman Cancer Center

5115 Centre Avenue, Hillman Cancer Center, 
Pittsburgh, PA 
412-623-4759
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Melissa Burgess is a Hematologist Oncology provider in Pittsburgh, Pennsylvania. Dr. Burgess is rated as an Elite provider by MediFind in the treatment of Chondrosarcoma. Her top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Merkel Cell Carcinoma, Chondrosarcoma, and Gamma Knife Radiosurgery.

Richard F. Riedel
Distinguished in Chondrosarcoma
Dr. Richard F. Riedel
Oncology
Distinguished in Chondrosarcoma
Dr. Richard F. Riedel
Oncology

Duke Cancer Center

20 Duke Medicine Cir, 
Durham, NC 
919-681-6900
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Richard Riedel is an Oncologist in Durham, North Carolina. Dr. Riedel is rated as a Distinguished provider by MediFind in the treatment of Chondrosarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Desmoid Tumor, and Angiosarcoma. Dr. Riedel is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Chondrosarcoma
Dr. Sant P. Chawla
Oncology | Hematology
Elite in Chondrosarcoma
Dr. Sant P. Chawla
Oncology | Hematology
2811 Wilshire Boulevard, Suite 414, 
Santa Monica, CA 
310-552-9999
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sant Chawla is a Hematologist and an Oncologist in Santa Monica, California. Dr. Chawla is rated as an Elite provider by MediFind in the treatment of Chondrosarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Synovial Sarcoma, and Myxoid Liposarcoma. Dr. Chawla is currently accepting new patients.

View All Doctors
What are the latest Chondrosarcoma Clinical Trials?
Phase II Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma
Phase II Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma
Who is this study for: Patients with Mesenchymal Chondrosarcoma
Enrollment Status: Recruiting
Publish Date: November 18, 2025
Intervention Type: Drug
Study Drug: Trabectedin
Study Phase: Phase 2

Summary: Prospective, uncontrolled, investigator-initiated, phase II clinical study to explore the activity of trabectedin in a population of patients aged ≥16 years with progressive, advanced (locally advanced or metastatic)

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Study of Ivosidenib in Participants ≥18 Years of Age With Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Study of Ivosidenib in Participants ≥18 Years of Age With Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
Enrollment Status: Recruiting
Publish Date: November 12, 2025
Intervention Type: Drug
Study Phase: Phase 3

Summary: Study CL3-95031-007 (CHONQUER) is a Phase 3, international, multicenter, double-blind, randomized, placebo-controlled study of orally administered ivosidenib. Participants are required to have a histopathological diagnosis consistent with isocitrate dehydrogenase-1 (IDH1) gene-mutated, locally advanced or metastatic conventional chondrosarcoma Grades 1, 2, or 3 and not eligible for curative resect...

View All Clinical Trials